The 10 drugs that cost Medicare Part B the most in 2018, according to a Moody’s Investors Service report:
- Eylea (Regeneron) — $2.57 billion
- Keytruda (Merck) — $1.81 billion
- Opdivo (Bristol-Myers Squibb) — $1.72 billion
- Rituxan (Roche) — $1.70 billion
- Prolia (Amgen) — $1.42 billion
- Neulasta (Amgen) — $1.37 billion
- Lucentis (Roche) — $1.22 billion
- Remicade (Johnson & Johnson) — $1.15 billion
- Avastin (Roche) — $1.01 billion
- Herceptin (Roche) — $822 million
More articles on pharmacy:
CVS offering emergency prescriptions in Puerto Rico
IPO of joint venture with Pfizer not discussed, GlaxoSmithKline says
Civica Rx inks deal to create its own drugs
